Eli Lilly Drops Glenmark In $500M ADHD Drug Suit
Eli Lilly and Co. agreed to drop patent infringement charges against generics maker Glenmark Pharmaceuticals Inc. USA as long as Glenmark adheres to any future rulings regarding a generic version of...To view the full article, register now.
Already a subscriber? Click here to view full article